샘플 요청 목록

 카트 문의
시장보고서
상품코드
1544084

세계의 뎅기열 백신 시장

Dengue Vaccine
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 193 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

뎅기열 백신 세계 시장은 2030년까지 16억 달러에 달할 것으로 예상됩니다

2023년 5억 8,900만 달러로 추정되는 뎅기열 백신 세계 시장은 2023년부터 2030년까지 연평균 15.8% 성장하여 2030년에는 16억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 정부 기관 최종 용도 부문은 CAGR 14.2%를 기록하여 분석 기간 종료 시점에 7억 7,460만 달러에 이를 것으로 예상됩니다. 병원 최종 용도 부문은 분석 기간 동안 CAGR 16.6%의 성장률을 나타낼 것으로 추정됩니다.

미국 시장은 1억 5,190만 달러로 추정, 중국은 연평균 20.1% 성장 전망

미국의 뎅기열 백신 시장은 2023년 1억 5,190만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2023-2030년 분석 기간 동안 20.1%의 연평균 복합 성장률(CAGR)을 나타내고, 2030년까지 4억 1,280만 달러 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 11.2%와 13.2%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 약 12.2%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

세계 뎅기열 백신 시장 - 주요 동향 및 촉진요인 요약

뎅기열 백신이란?

CYD-TDV 또는 상품명 Dengvaxia로도 알려진 뎅기열 백신은 뎅기열 바이러스에 의한 뎅기열을 예방하기 위해 승인된 최초의 백신입니다. 뎅기열은 모기를 매개로 전 세계 열대 및 아열대 기후에서 유행하며, 매년 수백만 명이 독감과 같은 심각한 증상과 생명을 위협할 수 있는 합병증으로 고통받고 있습니다. 이 백신은 뎅기열 바이러스의 약독화 버전을 뎅기열 바이러스 단백질을 발현하는 벡터로 사용하며, 4가지 바이러스 혈청형 모두에 반응하는 재조합 4가 생백신입니다. 이를 통해 면역체계를 자극하여 뎅기열 바이러스가 인체에 침입할 경우, 뎅기열 바이러스에 특이적으로 표적화된 방어 기전을 생성합니다. 그러나 이 백신은 혈청 양성 집단, 즉 과거에 바이러스에 감염된 적이 있는 집단에게만 사용하도록 권장되고 있습니다. 혈청 음성 집단, 즉 바이러스에 노출된 적이 없는 집단에서는 심각한 뎅기열에 걸릴 위험이 높아질 수 있기 때문입니다.

뎅기열 백신에 대한 임상적 지식과 공중보건상의 이점은 무엇인가?

뎅기열 백신에 대한 임상시험에서 혈청형과 연령대에 따라 효능에 차이가 있는 것으로 나타났으며, 전체 효능은 약 60% 정도입니다. 백신의 효능은 과거 뎅기열에 감염된 경험이 있는 사람에게서 두드러지게 높았으며, 이는 뎅기열이 유행하는 지역에서 백신의 유용성을 강조하고 있습니다. 이 백신의 공중보건학적 이점으로는 입원율 감소, 중증 뎅기열 환자 감소 등이 있으며, 이는 감염된 지역의 의료시스템의 부담을 줄이는 데 중요한 역할을 합니다. 따라서 이 백신은 특히 뎅기열이 많이 발생하는 지역에서 뎅기열 퇴치를 위한 중요한 수단으로 여겨지고 있습니다. 뎅기열 발생을 줄이면 생명을 구할 수 있을 뿐만 아니라 의료 비용과 질병으로 인한 생산성 저하로 인한 경제적 손실도 줄일 수 있습니다.

뎅기열 백신 개발의 과제와 유의사항은?

뎅기열 백신을 개발하기 위해서는 몇 가지 과제와 윤리적 고려가 필요합니다. 특히 뎅기열 바이러스에 감염된 적이 있는 사람을 식별하는 것입니다. 이를 위해서는 신뢰할 수 있는 혈청학적 검사가 필요하지만, 자원이 부족한 환경에서는 비용이 많이 들고 논리적으로도 어렵습니다. 또한, 백신 접종자 중 혈청 반응이 음성인 사람이 백신과 관련된 중증 뎅기열에 걸릴 위험이 있어 일부 지역에서는 초기 배포 후 논란과 사회적 불신으로 이어지기도 했습니다. 이러한 문제들로 인해 백신 접종에 따른 혜택을 극대화하고 위험을 최소화하기 위해서는 신중한 계획과 홍보 전략이 필요합니다. 또한 백신의 장기적인 안전성과 효능을 모니터링하기 위해서는 지속적인 연구와 감시가 필수적입니다.

뎅기열 백신 시장의 성장을 가속하는 요인은 무엇인가?

뎅기열 백신 시장 성장의 원동력은 여러 가지가 있지만, 주로 100개국 이상에서 높은 질병 부담으로 인해 효과적인 예방책에 대한 수요가 증가하고 있는 것이 주요 요인으로 꼽힙니다. 또한, 지구 온난화로 인한 유행 지역의 확대와 모기에게 이상적인 번식 조건을 만들어내는 도시화의 진전도 백신의 필요성에 박차를 가하고 있습니다. 또한, 해외여행 증가로 인해 뎅기열이 새로운 지역으로 계속 유입되고 있어 전 세계의 관심과 백신 접종에 대한 수요가 증가하고 있습니다. 백신 기술의 발전과 뎅기열 연구에 대한 자금 지원 증가로 뎅기열 백신의 개발 및 개선이 가속화되고 있으며, 보다 쉽게 접종할 수 있고 가격도 저렴해지고 있습니다. 민관 파트너십과 종합적인 뎅기열 예방 계획의 일환으로 백신 접종을 장려하는 세계보건기구(WHO)와 같은 세계보건기구(WHO)의 이니셔티브도 시장 성장에 기여하고 있습니다. 이러한 요인에 더해, 뎅기열의 영향에 대한 인식이 높아지고 예방 옵션에 대한 접근성이 높아지면서 뎅기열 백신 시장은 역동적으로 성장하고 있습니다.

조사 대상 기업 예시(주목받는 44개사)

  • Biological E. Ltd.
  • GlaxoSmithKline plc
  • Instituto Butantan
  • Panacea Biotec Ltd.
  • Sanofi SA
  • Takeda Pharmaceuticals Company Ltd.
  • Vabiotech

    목차

    제1장 조사 방법

    제2장 주요 요약

    • 시장 개요
    • 주요 기업
    • 시장 동향과 촉진요인
    • 세계 시장 전망

    제3장 시장 분석

    • 미국
    • 캐나다
    • 일본
    • 중국
    • 유럽
    • 프랑스
    • 독일
    • 이탈리아
    • 영국
    • 스페인
    • 러시아
    • 기타 유럽
    • 아시아태평양
    • 호주
    • 인도
    • 한국
    • 기타 아시아태평양
    • 라틴아메리카
    • 아르헨티나
    • 브라질
    • 멕시코
    • 기타 라틴아메리카
    • 중동
    • 이란
    • 이스라엘
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 기타 중동
    • 아프리카

    제4장 경쟁

    LSH 24.09.13

    Global Dengue Vaccine Market to Reach US$1.6 Billion by 2030

    The global market for Dengue Vaccine estimated at US$589.0 Million in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 15.8% over the analysis period 2023-2030. Government Institutions End-Use, one of the segments analyzed in the report, is expected to record a 14.2% CAGR and reach US$774.6 Million by the end of the analysis period. Growth in the Hospitals End-Use segment is estimated at 16.6% CAGR over the analysis period.

    The U.S. Market is Estimated at US$151.9 Million While China is Forecast to Grow at 20.1% CAGR

    The Dengue Vaccine market in the U.S. is estimated at US$151.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$412.8 Million by the year 2030 trailing a CAGR of 20.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.2% and 13.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

    Global Dengue Vaccine Market - Key Trends and Drivers Summarized

    What Is the Dengue Vaccine and How Does It Work Against the Virus?

    The dengue vaccine, also known as CYD-TDV or by its commercial name Dengvaxia, is the first vaccine approved for the prevention of dengue disease, caused by the dengue virus. Dengue is transmitted by mosquitoes and is prevalent in tropical and subtropical climates worldwide, affecting millions annually with severe flu-like symptoms and potentially life-threatening complications. The vaccine is a live recombinant tetravalent response to all four virus serotypes, utilizing a weakened version of the yellow fever virus as a vector to express dengue virus proteins. This stimulates the immune system to produce a defense mechanism specifically targeted against the dengue virus if it enters the human body. However, its use is recommended only in populations that are seropositive, meaning they have been previously infected by the virus, as the vaccine can increase the risk of severe dengue in seronegative individuals, those who have never been exposed to the virus.

    What Are the Clinical Insights and Public Health Benefits of the Dengue Vaccine?

    Clinical trials for the dengue vaccine have shown varied efficacy rates across different serotypes and age groups, with overall efficacy hovering around 60%. The vaccine's effectiveness is notably higher in individuals who have had a previous dengue infection, underscoring its utility in endemic regions where such exposure is common. Public health benefits of the vaccine include reduced hospitalization rates and a decrease in severe dengue cases, which are significant in helping ease the burden on healthcare systems in affected regions. The vaccine is thus considered a critical tool in the fight against dengue, particularly in high-prevalence areas. By reducing the incidence of dengue, it not only saves lives but also reduces economic loss related to healthcare costs and lost productivity due to illness.

    What Are the Challenges and Considerations in the Deployment of the Dengue Vaccine?

    The deployment of the dengue vaccine has faced several challenges and ethical considerations. One major issue is determining vaccine eligibility, particularly in identifying individuals previously infected by the dengue virus. This requires reliable serological testing, which can be costly and logistically challenging in resource-poor settings. There's also the risk of vaccine-related severe dengue in seronegative vaccine recipients, which has led to controversies and public distrust in some regions following early roll-outs. These challenges necessitate careful planning and public communication strategies to maximize benefits and minimize risks associated with vaccination. Additionally, ongoing research and surveillance are crucial to monitor long-term vaccine safety and effectiveness, especially as the virus evolves and different population dynamics come into play.

    What Drives the Growth in the Dengue Vaccine Market?

    The growth in the dengue vaccine market is driven by several factors, primarily the high burden of disease in over 100 countries, increasing the demand for effective preventive measures. The expansion of endemic areas due to global warming and increased urbanization, which create ideal breeding conditions for mosquitoes, also spur the need for vaccines. Furthermore, growing international travel continues to introduce dengue into new regions, raising global concern and demand for vaccination. Advances in vaccine technology and increased funding for dengue research have accelerated the development and improvement of dengue vaccines, making them more accessible and affordable. Public-private partnerships and initiatives by global health bodies like the World Health Organization (WHO) to promote vaccination as part of integrated dengue prevention plans also contribute to the growth of the market. These factors, combined with a heightened awareness of the impact of dengue and the availability of preventive options, ensure a dynamic and expanding market for the dengue vaccine.

    Select Competitors (Total 44 Featured) -

    • Biological E. Ltd.
    • GlaxoSmithKline plc
    • Instituto Butantan
    • Panacea Biotec Ltd.
    • Sanofi SA
    • Takeda Pharmaceuticals Company Ltd.
    • Vabiotech

    TABLE OF CONTENTS

    I. METHODOLOGY

    II. EXECUTIVE SUMMARY

    • 1. MARKET OVERVIEW
      • Influencer Market Insights
      • World Market Trajectories
      • Global Economic Update
      • Dengue Vaccine - Global Key Competitors Percentage Market Share in 2024 (E)
      • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • 2. FOCUS ON SELECT PLAYERS
    • 3. MARKET TRENDS & DRIVERS
      • Rising Global Prevalence of Dengue Fever Drives Urgency for Vaccine Development
      • Increasing Government and NGO Funding Propels Dengue Vaccine Research and Trials
      • Expansion of Vaccine Coverage in Endemic Regions Enhances Market Opportunities
      • Growing Public Health Initiatives Support Dengue Vaccination Programs
      • Integration of Dengue Vaccination in National Immunization Programs
      • Rising Travel and Migration Patterns Increase Demand for Dengue Vaccination
      • Growing Awareness Campaigns Enhance Public Acceptance of Dengue Vaccination
      • Growing Pediatric Population in Dengue-Prevalent Regions Drives Market Demand
      • Emergence of Vaccine Tourism in Dengue Endemic Regions
    • 4. GLOBAL MARKET PERSPECTIVE
      • TABLE 1: World Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 2: World Historic Review for Dengue Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 3: World 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
      • TABLE 4: World Recent Past, Current & Future Analysis for Government Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 5: World Historic Review for Government Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 6: World 16-Year Perspective for Government Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 7: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 8: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 9: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 10: World Recent Past, Current & Future Analysis for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 11: World Historic Review for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 12: World 16-Year Perspective for NGOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 13: World Dengue Vaccine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

    III. MARKET ANALYSIS

    • UNITED STATES
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
      • TABLE 14: USA Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 15: USA Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 16: USA 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • CANADA
      • TABLE 17: Canada Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 18: Canada Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 19: Canada 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • JAPAN
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
      • TABLE 20: Japan Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 21: Japan Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 22: Japan 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • CHINA
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
      • TABLE 23: China Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 24: China Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 25: China 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • EUROPE
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
      • TABLE 26: Europe Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 27: Europe Historic Review for Dengue Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 28: Europe 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
      • TABLE 29: Europe Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 30: Europe Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 31: Europe 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • FRANCE
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
      • TABLE 32: France Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 33: France Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 34: France 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • GERMANY
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
      • TABLE 35: Germany Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 36: Germany Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 37: Germany 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • ITALY
      • TABLE 38: Italy Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 39: Italy Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 40: Italy 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • UNITED KINGDOM
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
      • TABLE 41: UK Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 42: UK Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 43: UK 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • SPAIN
      • TABLE 44: Spain Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 45: Spain Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 46: Spain 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • RUSSIA
      • TABLE 47: Russia Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 48: Russia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 49: Russia 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • REST OF EUROPE
      • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 51: Rest of Europe Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 52: Rest of Europe 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • ASIA-PACIFIC
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
      • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 54: Asia-Pacific Historic Review for Dengue Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 55: Asia-Pacific 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
      • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 57: Asia-Pacific Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 58: Asia-Pacific 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • AUSTRALIA
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
      • TABLE 59: Australia Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 60: Australia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 61: Australia 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • INDIA
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
      • TABLE 62: India Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 63: India Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 64: India 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • SOUTH KOREA
      • TABLE 65: South Korea Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 66: South Korea Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 67: South Korea 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • REST OF ASIA-PACIFIC
      • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 69: Rest of Asia-Pacific Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • LATIN AMERICA
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
      • TABLE 71: Latin America Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 72: Latin America Historic Review for Dengue Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 73: Latin America 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
      • TABLE 74: Latin America Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 75: Latin America Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 76: Latin America 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • ARGENTINA
      • TABLE 77: Argentina Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 78: Argentina Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 79: Argentina 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • BRAZIL
      • TABLE 80: Brazil Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 81: Brazil Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 82: Brazil 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • MEXICO
      • TABLE 83: Mexico Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 84: Mexico Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 85: Mexico 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • REST OF LATIN AMERICA
      • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 87: Rest of Latin America Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 88: Rest of Latin America 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • MIDDLE EAST
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
      • TABLE 89: Middle East Recent Past, Current & Future Analysis for Dengue Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
      • TABLE 90: Middle East Historic Review for Dengue Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 91: Middle East 16-Year Perspective for Dengue Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
      • TABLE 92: Middle East Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 93: Middle East Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 94: Middle East 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • IRAN
      • TABLE 95: Iran Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 96: Iran Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 97: Iran 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • ISRAEL
      • TABLE 98: Israel Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 99: Israel Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 100: Israel 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • SAUDI ARABIA
      • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 102: Saudi Arabia Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 103: Saudi Arabia 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • UNITED ARAB EMIRATES
      • TABLE 104: UAE Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 105: UAE Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 106: UAE 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • REST OF MIDDLE EAST
      • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 108: Rest of Middle East Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 109: Rest of Middle East 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030
    • AFRICA
      • Dengue Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
      • TABLE 110: Africa Recent Past, Current & Future Analysis for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
      • TABLE 111: Africa Historic Review for Dengue Vaccine by End-Use - Government Institutions, Hospitals and NGOs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
      • TABLE 112: Africa 16-Year Perspective for Dengue Vaccine by End-Use - Percentage Breakdown of Value Sales for Government Institutions, Hospitals and NGOs for the Years 2014, 2024 & 2030

    IV. COMPETITION

    • 샘플 요청 목록
    0 건의 상품을 선택 중
    목록 보기
    전체삭제